BiotechTube
TargED Biopharmaceuticals

TargED Biopharmaceuticals

Utrecht, Netherlands· Est.
targedbiopharmaceuticals.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $28.5M

Overview

TargED Biopharmaceuticals is a private, clinical-stage biotech focused on revolutionizing thrombosis treatment with its targeted enzyme delivery platform. Its lead asset, TGD001, is a novel biologic designed to break down blood clots irrespective of their composition and is currently in Phase 1 development for immune Thrombotic Thrombocytopenic Purpura (iTTP) and Acute Ischemic Stroke (AIS). The company has strong academic roots, experienced leadership with prior success in the thrombosis space (Caplacizumab), and has secured significant venture funding, totaling over €60 million, to advance its pipeline.

ThrombosisHematologyCardiovascularNeurology

Technology Platform

Targeted Enzyme Delivery platform using VHH (nanobody) antibodies to deliver thrombolytic enzymes specifically to blood clot sites for localized, safer thrombolysis.

Funding History

2
Total raised:$28.5M
Series A$25M
Seed$3.5M

Opportunities

The massive global market for safer, more effective thrombolytics in conditions like stroke and heart attack represents a multi-billion dollar opportunity.
Orphan drug development in iTTP offers a faster, de-risked regulatory pathway to initial approval and proof-of-concept.
The platform's potential to treat any clot type could position TGD001 as a universal, paradigm-shifting therapy.

Risk Factors

High clinical development risk: Phase 2 trials must demonstrate efficacy and a superior safety profile versus standard care.
Competitive and regulatory risks are significant in the crowded cardiovascular space.
The platform's broad applicability across all thrombosis types remains unproven in humans.

Competitive Landscape

TargED competes with existing systemic thrombolytics (e.g., tPA, tenecteplase) and a pipeline of novel anticoagulants/antiplatelets. Its key differentiation is targeted, localized action to reduce bleeding risk. Direct competitors include other companies developing targeted thrombolytics or clot-modifying therapies, but the VHH-enzyme fusion approach appears unique.

More companies in Biologics / Biosimilars →More companies in Netherlands →